Taxol: A novel investigational antimicrotubule agent

Eric K. Rowinsky, Lorraine A. Cazenave, Ross C Donehower

Research output: Contribution to journalArticle

Abstract

Microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics. Despite this fact, new antimicrotubule agents that possess unique mechanisms of cytotoxic action and have broader antineoplastic spectra than the vinca alkaloids have not been introduced over the last several decades - until the recent development of taxol. Unlike classical antimicrotubule agents like colchicine and the vinca alkaloids, which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules. Taxol has demonstrated broad activity in preclinical screening studies, and antineoplastic activity has been observed in several classically refractory tumors. These tumors include cisplatinresistant ovarian carcinoma in phase II trials and malignant melanoma and non-small cell lung carcinoma in phase I studies. Taxol's structural complexity has hampered the development of feasible processes for synthesis, and its extreme scarcity has limited the use of a conventional, broad-scale screening approach for evaluation of clinical antitumor activity. However, taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development.

Original languageEnglish (US)
Pages (from-to)1247-1259
Number of pages13
JournalJournal of the National Cancer Institute
Volume82
Issue number15
StatePublished - Aug 1 1990

Fingerprint

Paclitaxel
Microtubules
Tumors
Alkaloids
Tumor
Vinca Alkaloids
Screening
Depolymerization
Antineoplastic Agents
Action Spectrum
Refractory materials
Melanoma
Polymerization
Lung
Neoplasms
Cells
Clinical Trials
Colchicine
Tubulin
Extremes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Taxol : A novel investigational antimicrotubule agent. / Rowinsky, Eric K.; Cazenave, Lorraine A.; Donehower, Ross C.

In: Journal of the National Cancer Institute, Vol. 82, No. 15, 01.08.1990, p. 1247-1259.

Research output: Contribution to journalArticle

Rowinsky, Eric K. ; Cazenave, Lorraine A. ; Donehower, Ross C. / Taxol : A novel investigational antimicrotubule agent. In: Journal of the National Cancer Institute. 1990 ; Vol. 82, No. 15. pp. 1247-1259.
@article{6a4aea7bf95e4870a7664f0f71363c3d,
title = "Taxol: A novel investigational antimicrotubule agent",
abstract = "Microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics. Despite this fact, new antimicrotubule agents that possess unique mechanisms of cytotoxic action and have broader antineoplastic spectra than the vinca alkaloids have not been introduced over the last several decades - until the recent development of taxol. Unlike classical antimicrotubule agents like colchicine and the vinca alkaloids, which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules. Taxol has demonstrated broad activity in preclinical screening studies, and antineoplastic activity has been observed in several classically refractory tumors. These tumors include cisplatinresistant ovarian carcinoma in phase II trials and malignant melanoma and non-small cell lung carcinoma in phase I studies. Taxol's structural complexity has hampered the development of feasible processes for synthesis, and its extreme scarcity has limited the use of a conventional, broad-scale screening approach for evaluation of clinical antitumor activity. However, taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development.",
author = "Rowinsky, {Eric K.} and Cazenave, {Lorraine A.} and Donehower, {Ross C}",
year = "1990",
month = "8",
day = "1",
language = "English (US)",
volume = "82",
pages = "1247--1259",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Taxol

T2 - A novel investigational antimicrotubule agent

AU - Rowinsky, Eric K.

AU - Cazenave, Lorraine A.

AU - Donehower, Ross C

PY - 1990/8/1

Y1 - 1990/8/1

N2 - Microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics. Despite this fact, new antimicrotubule agents that possess unique mechanisms of cytotoxic action and have broader antineoplastic spectra than the vinca alkaloids have not been introduced over the last several decades - until the recent development of taxol. Unlike classical antimicrotubule agents like colchicine and the vinca alkaloids, which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules. Taxol has demonstrated broad activity in preclinical screening studies, and antineoplastic activity has been observed in several classically refractory tumors. These tumors include cisplatinresistant ovarian carcinoma in phase II trials and malignant melanoma and non-small cell lung carcinoma in phase I studies. Taxol's structural complexity has hampered the development of feasible processes for synthesis, and its extreme scarcity has limited the use of a conventional, broad-scale screening approach for evaluation of clinical antitumor activity. However, taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development.

AB - Microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics. Despite this fact, new antimicrotubule agents that possess unique mechanisms of cytotoxic action and have broader antineoplastic spectra than the vinca alkaloids have not been introduced over the last several decades - until the recent development of taxol. Unlike classical antimicrotubule agents like colchicine and the vinca alkaloids, which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules. Taxol has demonstrated broad activity in preclinical screening studies, and antineoplastic activity has been observed in several classically refractory tumors. These tumors include cisplatinresistant ovarian carcinoma in phase II trials and malignant melanoma and non-small cell lung carcinoma in phase I studies. Taxol's structural complexity has hampered the development of feasible processes for synthesis, and its extreme scarcity has limited the use of a conventional, broad-scale screening approach for evaluation of clinical antitumor activity. However, taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development.

UR - http://www.scopus.com/inward/record.url?scp=0025333168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025333168&partnerID=8YFLogxK

M3 - Article

C2 - 1973737

AN - SCOPUS:0025333168

VL - 82

SP - 1247

EP - 1259

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 15

ER -